Epiomic Epidemiology Series: Atopic Dermatitis Forecast in 21 Major Markets 2018–2028

June 2018 | 92 pages | ID: EF2DABFCC4EEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Atopic Dermatitis in 21 Major Markets

Atopic Dermatitis, also known as eczema, is a common disorder of the epidermis of the skin causing dryness, itchiness, red rashes, inflammation, sores and blisters. It occurs mostly in early childhood and can develop from exposure to allergens and irritants, such as dust mites, pollen, peanuts and so forth. The prognosis for most patients is improvement in symptoms, and by adulthood it may disappear altogether.

This report provides the current prevalent population for Atopic Dermatitis across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, South Africa, Japan, China, South Korea, Singapore, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of severity, location and IgE levels of Atopic Dermatitis, to name a few. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Atopic Dermatitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Atopic Dermatitis include:

• Asthma
• Rhinitis
• Allergies (Food- or Inhalant-related)
• Rashes
• Eczemic lesions

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Able to quantify patient populations in global Atopic Dermatitis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Atopic Dermatitis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Atopic Dermatitis prevalent population.
• Identify sub-populations within Atopic Dermatitis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Atopic Dermatitis patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR ATOPIC DERMATITIS
FEATURES OF ATOPIC DERMATITIS PATIENTS
  SIGNS AND SYMPTOMS
  OTHER FEATURES
  COMORBIDITIES OF ATOPIC DERMATITIS PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Prevalence of atopic dermatitis, total (000s)
Table 2. Prevalence of atopic dermatitis, males (000s)
Table 3. Prevalence of atopic dermatitis, females (000s)
Table 4. Patients with atopic dermatitis by average no. of days per year with symptoms, total (000s)
Table 5. Patients with atopic dermatitis by disease severity, total (000s)
Table 6. Patients with atopic dermatitis by frequency of flare in past 12 months, total (000s)
Table 7. Atopic dermatitis patients with excessive dryness/scaling of the skin, total (000s)
Table 8. Atopic dermatitis patients with red or inflamed rash, total (000s)
Table 9. Atopic dermatitis patients with blisters/bumps, total (000s)
Table 10. Atopic dermatitis patients with thickening of the skin, total (000s)
Table 11. Atopic dermatitis patients with open or oozing sores, total (000s)
Table 12. Atopic dermatitis patients with lesions on arms or hands, total (000s)
Table 13. Atopic dermatitis patients with lesions on legs or feet, total (000s)
Table 14. Atopic dermatitis patients with lesions on head, face or scalp, total (000s)
Table 15. Atopic dermatitis patients with lesions on chest, abdomen or back, total (000s)
Table 16. Atopic dermatitis patients with lesions on groin or underarm, total (000s)
Table 17. Atopic dermatitis patients with lesions on the skinfold of arms or legs, total (000s)
Table 18. Atopic dermatitis patients with lesions on elbows or knees, total (000s)
Table 19. Patients with atopic dermatitis by IgE levels (kU/L), total (000s)
Table 20. Atopic dermatitis patients with filaggrin mutation, total (000s)
Table 21. Patients with atopic dermatitis by disease inheritance status, total (000s)
Table 22. Atopic dermatitis patients with asthma, total (000s)
Table 23. Atopic dermatitis patients with allergic rhinitis, total (000s)
Table 24. Atopic dermatitis patients with contact dermatitis, total (000s)
Table 25. Atopic dermatitis patients with psoriasis, total (000s)
Table 26. Atopic dermatitis patients with vitiligo, total (000s)
Table 27. Atopic dermatitis patients with allergy to egg white, total (000s)
Table 28. Atopic dermatitis patients with allergy to cow milk, total (000s)
Table 29. Atopic dermatitis patients with allergy to peanuts, total (000s)
Table 30. Atopic dermatitis patients with inhalant allergy to house dust mite, total (000s)
Table 31. Atopic dermatitis patients with inhalant allergy to cat dander, total (000s)
Table 32. Atopic dermatitis patients with inhalant allergy to tree pollen, total (000s)
Table 33. Atopic dermatitis patients with inhalant allergy to grass pollen, total (000s)
Table 34. Atopic dermatitis patients with inhalant allergy to Alternaria, total (000s)
Table 35. Abbreviations and acronyms used in the report
Table 36. USA prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 37. USA prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 38. Canada prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 39. Canada prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 40. France prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 41. France prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 42. Germany prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 43. Germany prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 44. Italy prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 45. Italy prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 46. Spain prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 47. Spain prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 48. UK prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 49. UK prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 50. Poland prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 51. Poland prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 52. Netherlands prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 53. Netherlands prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 54. Russia prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 55. Russia prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 56. Turkey prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 57. Turkey prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 58. South Africa prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 59. South Africa prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 60. Japan prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 61. Japan prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 62. China prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 63. China prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 64. South Korea prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 65. South Korea prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 66. Singapore prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 67. Singapore prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 68. India prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 69. India prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 70. Australia prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 71. Australia prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 72. Brazil prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 73. Brazil prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 74. Mexico prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 75. Mexico prevalence of atopic dermatitis by 5-yr age cohort, females (000s)
Table 76. Argentina prevalence of atopic dermatitis by 5-yr age cohort, males (000s)
Table 77. Argentina prevalence of atopic dermatitis by 5-yr age cohort, females (000s)